1. Home
  2. VTSI vs RNTX Comparison

VTSI vs RNTX Comparison

Compare VTSI & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VirTra Inc.

VTSI

VirTra Inc.

N/A

Current Price

$2.62

Market Cap

51.0M

ML Signal

N/A

Logo Rein Therapeutics Inc.

RNTX

Rein Therapeutics Inc.

N/A

Current Price

$0.68

Market Cap

57.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VTSI
RNTX
Founded
1993
2001
Country
United States
United States
Employees
N/A
10
Industry
Miscellaneous manufacturing industries
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.0M
57.8M
IPO Year
1999
2017

Fundamental Metrics

Financial Performance
Metric
VTSI
RNTX
Price
$2.62
$0.68
Analyst Decision
Strong Buy
Buy
Analyst Count
2
2
Target Price
★ $6.25
$6.00
AVG Volume (30 Days)
26.9K
★ 443.5K
Earning Date
11-12-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 44.16
EPS
★ N/A
N/A
Revenue
★ $185,971.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$27.40
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.54
$0.54
52 Week High
$6.08
$2.18

Technical Indicators

Market Signals
Indicator
VTSI
RNTX
Relative Strength Index (RSI) 42.00 48.32
Support Level $2.54 $0.54
Resistance Level $2.82 $0.87
Average True Range (ATR) 0.12 0.07
MACD 0.01 0.01
Stochastic Oscillator 32.14 59.50

Price Performance

Historical Comparison
VTSI
RNTX

About VTSI VirTra Inc.

VirTra Inc is a U.S.-based company that is engaged in the sale and development of judgmental use-of-force training simulators and firearms training simulators for law enforcement, military, and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company include installation, training, limited warranties, service agreements, and related support. The company operates in six segments, which include Simulators and Accessories, Extended Service, Customized software and Custom content, Installation and Training, Design and Prototyping, and Subscription Training Equipment Partnership. The majority of its revenue is generated from the Simulators and Accessories segment.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: